Search Results for “EC” – Page 34 – media

AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 bn in sales by 2027

In 2014, the FDA approved the first (adenosine diphosphate-ribose) polymerase (PARP) inhibitor AstraZeneca/Merck’s Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients who have received three or more prior lines of chemotherapy. Since then, the PARP inhibitors market has made significant strides, but Lynparza maintains its dominance with projected global sales of $4 billion by 2027, according to an analyst consensus forecast by GlobalData. GlobalData’s analyst consensus reveals that high sales projections underscore Lynparza’s role in treating multiple cancer types, including ovarian, pancreatic, prostate, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Expected revenues in these indications will reach over 68 per cent of the global PARP inhibitors market by 2027. GlaxoSmithKline’s (GSK) Zejula (niraparib) holds the second position with over $1.6 billion in sales and 28 per cent of the market share. Most of Lynparza’s sales come from ovarian and HER2-negative breast cancer treatment. Biswajit Podder, ...
- Source: https://www.expresspharma.in/astrazenecas-lynparza-to-dominate-parp-inhibitors-market-with-4-bn-in-sales-by-2027-globaldata/
- 162
- May 4, 2024
DP Technology DevDay 2024 Showcases Large Science Models and Announces Open Science Initiative

BEIJING, April 29, 2024 /PRNewswire/ — In recent years, the rapid development of artificial intelligence has introduced new possibilities across numerous scientific disciplines. As an AI for Science pioneer, DP Technology is continually collaborating with partners to explore the transformative impact AI can bring to science. During its DevDay held in Beijing on April 12th, DP Technology showcased a series of large science models, including the DPA large atomic model[1], Uni-Mol 3D molecular model[2], Uni-Fold protein folding model[3], Uni-RNA ribonucleic acid model[4], and Uni-SMART large language model for multimodal scientific literature[5] among others. About DP Technology DP Technology is a global leader in the “AI for Science” research paradigm, where AI learns scientific principles and data, then tackles key challenges in scientific research and industrial R&D. DP’s commitment to interdisciplinary research has led to the creation of the “DP Particle Universe,” an array of pre-trained large science ...
- Source: https://en.prnasia.com/releases/global/dp-technology-devday-2024-showcases-large-science-models-and-announces-open-science-initiative-445188.shtml
- 105
- May 3, 2024
Lupin receives EIR from USFDA for its Aurangabad manufacturing facility

The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI) Lupin has announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Aurangabad manufacturing facility. The inspection was conducted from March 6 to March 15, 2024. The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI). Nilesh Gupta, Managing Director, Lupin said, “We are pleased to receive the EIR with VAI status from the USFDA as an outcome of the recent inspection of our Aurangabad facility. It is a testament to our commitment to consistently upholding the highest standards of compliance and providing high-quality healthcare solutions to patients worldwide.”
- Source: https://www.lupin.com/lupin-receives-eir-from-us-fda-for-its-aurangabad-manufacturing-facility/
- 92
- May 3, 2024
Ono Pharmaceutical acquires cancer-focused biopharma Deciphera for $2.4bn

Deciphera Pharmaceuticals is set to be acquired in a $2.4bn buyout, as the biopharma announced that it has commenced a definitive merger agreement with Ono Pharmaceutical. Under the terms of the offered transaction, Ono will make a cash purchase of all outstanding shares of Deciphera’s common stock at $25.60 per share and subsequently merge Deciphera with a wholly-owned subsidiary of Ono upon the deal’s completion. The deal has been unanimously approved by both companies’ boards of directors and is expected to close in Q3 2024. Following the announcement of acquisition, Deciphera’s stock has jumped 71.9%. Waltham, Massachusetts-based Deciphera brings to the table an extensive kinase inhibitor pipeline, kinase drug discovery expertise, and a strong commercial and sales platform in the US and European markets that is meant to advance Ono’s capabilities and presence in the oncology space. Upon the successful completion of the acquisition, Ono will gain access to Deciphera’s ...
- Source: drugdu
- 106
- May 3, 2024
Six Biopharma Companies to Watch at MedCity INVEST Pitch Perfect Contest

The MedCity INVEST conference is scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, The companies will offer a window into some of the promising treatments under development such as different types of cancers to muscular dystrophy. Space is limited so register today! By Stephanie Baum Biopharma companies are responsible for some of the most transformative, life-changing technologies in medicine from gene therapy to immunotherapy. At the MedCity INVEST conference scheduled for May 21-22 at the Ritz Carlton hotel in Chicago, six biopharma companies will give attendees a window into some of the promising treatments under development. MedCity News Senior Biopharma Reporter Frank Vinluan will moderate the biopharma track of the startup contest Pitch Perfect. One judge confirmed for the track is Meredith Wilkerson, an investment principal with Plains Ventures who serves as the primary subject matter expert for evaluating life sciences and biotech investment opportunities. Wilkerson will also ...
- Source: drugdu
- 94
- May 2, 2024
BIOSECURE bill targets more Chinese companies as biotechs and their customers adapt to defunding

On Wednesday, 3 April, 2024, a letter from the House’s Select Committee on the Chinese Communist Party recommended more companies to add to the Pentagon’s list of firms that are allegedly working with the Chinese military. The letter identifies several companies, including two headquartered in California—Innomics (Sunnyvale, CA, US) and Axbio (Santa Clara, CA, US)—as potentially Chinese military-backed companies, and implied the companies may have tried to hide their affiliation with Chinese-headquartered BGI Genomics (Shenzhen, China), which has been on the security risk list since 2022. Other Chinese companies recommended for the list are Origincell (Shanghai, China), Vazyme Biotech (Nanjing, China), and STOmics (Shenzhen, China). The letter states that Innomics recently registered to conduct business operations in Kentucky under BGI. Innomics provides sequencing services to institutional and corporate clients for research purposes and STOmics sells lab kits and reagents. BGI asserts that both Innomics and STOmics belong to BGI but ...
- Source: drugdu
- 102
- May 2, 2024
Technoderma Medicines Advances TDM-180935 Atopic Dermatitis Clinical Program with Phase 2 Trial

CHENGDU, China, April 29, 2024 /PRNewswire/ — Technoderma Medicines, Inc. (“the Company”), a clinical stage biopharmaceutical company, is pleased to report the Company has begun dosing patients in its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment. This clinical trial in the Atopic Dermatitis (AD) program includes 8 weeks dosing of two different active formulation strengths and placebo in a study entitled, “A Randomized, Vehicle-Controlled, Parallel Group Study of Topical TDM-180935 to Evaluate the Preliminary Efficacy, Safety, Tolerability, and Pharmacokinetics in Atopic Dermatitis Patients”. It is a randomized, vehicle-controlled, parallel group comparison study with an open-label PK sub-study. Objectives are to evaluate the safety and efficacy of topical TDM-180935 as well aspharmacokinetics. Seven U.S. clinical sites are currently participating in this study under an open IND with FDA. Arthur P. Bertolino, MD, PhD, MBA, Chief Medical Officer at Technoderma Medicines commented, “We expect the current study to support ...
- Source: https://en.prnasia.com/releases/global/technoderma-medicines-advances-tdm-180935-atopic-dermatitis-clinical-program-with-phase-2-trial-445242.shtml
- 75
- May 2, 2024
Degu Insulin Liraglutide Injection was approved for clinical application

Tonghua Dongbao Pharmaceutical Co., Ltd (hereinafter referred to as “Tonghua Dongbao”) has recently obtained the clinical trial approval notification of Degu Insulin Liraglutide Injection issued by the Center for Drug Evaluation (CDE) of the State Drug Administration. The clinical approval of Degu Insulin Liraglutide Injection is another significant progress in the research and development of insulin analog GLP-1RA compound preparation, which will further enhance the company’s competitiveness in the field of endocrine therapy. In the future, the Company is expected to accelerate the process of clinical trials and speed up the approval and listing of its products by virtue of its R&D advantages accumulated in the field of diabetes treatment over the years, so as to provide richer and better choices for clinical medication. Degu Insulin Liraglutide Injection has a broad market prospect in the future, and the market scale shows a rapid growth trend. Its original Degu Insulin Liraglutide ...
- Source: drugdu
- 80
- May 1, 2024
First of Its Kind Universal Tool to Revolutionize Sample Collection for Diagnostic Tests

The COVID pandemic has dramatically reshaped the perception of diagnostics. Post the pandemic, a groundbreaking device that combines sample collection and processing into a single, easy-to-use disposable unit could revolutionize the way samples are collected for diagnostic tests. ReadyGo Diagnostics’ (Bath, UK) Sampler device incorporates both the swab and collection buffers into one device, making it exceptionally user-friendly. It is the world’s first universal tool of its kind that ensures convenience, reliability, and reproducibility right from the initial step of a diagnostic test. The patented technology behind the ReadyGo Sampler uses specially engineered materials that not only allow the device to collect the exact amount of sample required instantly but also rapidly break open viruses and bacteria, making them readily detectable in specific tests. The ReadyGo Sampler device is intended to be a more user-oriented alternative to conventional swab-based sample collection methods by combining sample collection and processing into one ...
- Source: drugdu
- 79
- May 1, 2024
ETH Zurich researchers use AI to develop drug molecules based on protein structures

Researchers from ETH Zurich have developed a new generative artificial intelligence (AI)-based computer process to develop drug molecules based on a protein’s three-dimensional surface. The new process could revolutionise drug research, making it possible to generate active pharmaceutical ingredients quickly and easily. The new computer process’ algorithm was developed in collaboration with ETH’s professor Gisbert Schneider and former doctoral student Kenneth Atz, using AI to design new active pharmaceutical ingredients. Researchers trained the AI model with information from hundreds of thousands of known interactions between chemical molecules and the corresponding three-dimensional protein structures. The algorithm generates the blueprints for potential drug molecules that can increase or inhibit the activity of proteins with a known three-dimensional shape. The generative AI then designs molecules that bind specifically to the protein according to the lock-and-key principle to be interacted with. “This means that when designing a drug molecule, we can be sure that ...
- Source: drugdu
- 78
- May 1, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.